The chance of finding a possible cure for the deadly Acquired Immune Deficiency Syndrome (AIDS) Virus may be closer as a Nigerian Professor Isaiah Ibeh, on Tuesday, announced the development of a new drug that can cure HIV and AIDS.

According to Prof. Isaiah Ibeh, who is also the Dean, School of Basic Medical Sciences, University of Benin, Nigeria; the herbal cure prepared for the disease has already undergone “series of test.”

Ibeh stated that he had begun research on the ailment in 2010 and his work has culminated in the development of “Deconcotion X (DX)–Liquid or Bioclean 11 for the cure of HIV and AIDS.”

Nigerian Newspaper, The Punch, spoke to the University Public Relations Officer, Harrison Osarenren, who confirmed that “The professor just developed a drug that can cure HIV/AIDS and it has been tested. He has solution to AIDS.”

Ibeh, who had earlier made his assertion public to the News Agency of Nigeria (NAN) said, “We are at the threshold of making history, in the sense that we seem to have with us something that will permanently take care of what over time seems to have defied all solutions. We are talking about the latest discovery of an oral drug made from plants extraction in Nigeria for the possible cure for the pandemic, HIV and AIDS virus.’’

“The existing retroviral drugs are intervention drugs for the management of AIDS but our new discovery is a possible cure,” the Professor said.

“We have tried to look at the product first; its toxicological analysis and discovered that it has a large safety margin. This means that if animals or human beings are exposed to it, they will not suffer any serious harm at all from the exposure.”

He added that the toxicological analysis also helped in knowing the quantity that can be conveniently given to animals which will ensure that nothing untoward happens.

“We have also done the bacteriological analysis on it, after which we looked at its effect on the virus and the result was quite revealing and refreshing.’’

Ibeh also confirmed that the drug had been exposed to series of medical examination both in Nigeria and in the USA;  adding that it (the drug) had performed well on tested HIV patients  with evidence of total restoration of damaged tissues.

“The result showed an increase in the body weight of the individual administered with DX. The body weight was statistically significant when compared with the control group,” he affirmed.

The Professor said that further tests were being conducted to determine “at what point will a patient become negative after being administered the drug?”

“This verification is necessary because it is what is used to measure whether infection is still there or not. So we need to know the siro-convention time. But preliminary results showed that of the five latest patients orally administered with the drugs, our findings is that up to seven months three of them were siro negative while two were still faintly positive.’’

Ibeh however appealed to the Federal Government and relevant bodies to assist the university with relevant equipment to sustain the research.

HIV/AIDS is one of the major health concerns in Africa. According to a report by the United Nations Programme on AIDS (UNAIDS); as at 2011, about 23.5 million Sub-Saharan Africans are HIV-positive; accounting for about 69 percent of the global total. The report also confirmed that nearly 6.2 million people were receiving antiretroviral therapy in sub-Saharan Africa in 2011, up from just 100,000 in 2003.


Elsewhere on Ventures

Triangle arrow